Denali Therapeutics Inc (NASDAQ:DNLI) has been assigned a consensus broker rating score of 1.17 (Strong Buy) from the three analysts that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company.

Analysts have set a 12 month consensus price objective of $24.00 for the company, according to Zacks. Zacks has also given Denali Therapeutics an industry rank of 160 out of 265 based on the ratings given to related companies.

Several research firms recently issued reports on DNLI. JPMorgan Chase & Co. began coverage on Denali Therapeutics in a research note on Tuesday. They issued an “overweight” rating and a $24.00 price target for the company. Morgan Stanley began coverage on Denali Therapeutics in a research note on Tuesday. They issued an “overweight” rating and a $25.00 price target for the company. Evercore ISI began coverage on Denali Therapeutics in a research note on Tuesday. They issued an “outperform” rating and a $23.00 price target for the company. Finally, Goldman Sachs Group began coverage on Denali Therapeutics in a research note on Tuesday. They issued a “neutral” rating for the company.

Denali Therapeutics (NASDAQ DNLI) opened at $16.65 on Thursday. The firm has a market capitalization of $1,460.00 and a P/E ratio of -16.17. Denali Therapeutics has a 1-year low of $14.72 and a 1-year high of $22.95.

In other news, major shareholder Douglas K. Bratton purchased 275,000 shares of Denali Therapeutics stock in a transaction that occurred on Tuesday, December 12th. The stock was acquired at an average cost of $18.00 per share, for a total transaction of $4,950,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

TRADEMARK VIOLATION NOTICE: “Zacks: Denali Therapeutics Inc (DNLI) Receives Consensus Recommendation of “Strong Buy” from Analysts” was originally published by American Banking News and is the property of of American Banking News. If you are reading this piece on another website, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this piece can be read at https://www.americanbankingnews.com/2018/01/04/zacks-denali-therapeutics-inc-dnli-receives-consensus-recommendation-of-strong-buy-from-analysts.html.

About Denali Therapeutics

Denali Therapeutics Inc is a biotechnology company. The Company is focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and others. The Company is developing a diversified portfolio of therapeutics, based on scientific insights into the genetic causes and biological processes underlying neurodegenerative disease.

Get a free copy of the Zacks research report on Denali Therapeutics (DNLI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.